Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of intradermal tilsotolimod before sentinel lymph node biopsy in high-risk primary melanoma
NL-OMON52549Phase 2Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jan 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tilsotolimod in cutaneous melanoma (CM), sponsored by Vrije University Medical Center. Primary endpoint: Sentinel lymph node tumor status. Started Jan 2020; status: recruiting.
02
Drugs
tilsotolimod
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON52549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52549.